Website Search
ID 15045

Why tumor typing is important, David Botstein

Interviewee: David Botstein. David Botstein talks about how tumor typing using genome-wide analysis will help doctors determine the most appropriate treatments for their patients. (DNAi Location: Applications > Genes and medicine > Genetic profiling > David Botstein > Why tumor typing is important)
And the reason that's important for patients is that treatments that work for one kind of tumor may not work for another kind of tumor, even though they look the same to the pathologist. And under the circumstances where we can separate the apples from the oranges, we can actually apply the cure for the orange disease to the oranges, and not have it confused by the response of the apples which may be no response or even a bad response. In leukemia, especially childhood leukemia, this has been very successful with even very standard treatments, so that we believe is going to be an immediate benefit to the patients.
david botstein,childhood leukemia,genetic profiling,location applications,dnai,interviewee,pathologist,leukemia,oranges,apples,genes,dna,doctors,circumstances,cancer,benefit,medicine
Creative Commons License This work by Cold Spring Harbor Laboratory is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 United States License.

Related content:

15046. Better cancer therapies by identifying oncogenes, David Botstein
David Botstein discusses how identifying the molecular mechanisms of cancer will lead to the development of improved therapies.
15048. Better diagnosis, David Botstein
David Botstein talks about the goal of using microarray analysis to improve cancer diagnosis.
15047. Promises of genomics, David Botstein
David Botstein (sitting with Pat Brown) talks about how innovations in genomics might lead to personalized medicine.
15082. Shutting down cancer with Gleevec, Brian Druker
Brian Druker reflects on the importance of understanding the causes of cancer for developing new treatments.
15057. Before and after Gleevec, Brian Druker
Brian Druker talks about the drug he developed as a turning point in the war on cancer.
15041. Getting the diagnosis of chronic myeloid leukemia, Bud
Bud recounts receiving the diagnosis that he had chronic myeloid leukemia.
15055. Using DNA science to control CML, Brian Druker
Brian Druker talks about how the drug he designed targets the molecular cause of CML.
15053. Gene profile and response to treatment, Stephen Fodor
Stephen Fodor talks about how an individual's gene expression profile can help determine what therapies might work best.
15040. Using DNA microarrays to study cancer, Patrick Brown
Pat Brown talks about using microarrays to discover the differences between cancer cells and healthy cells.
15525. How Gleevec works to alleviate symptoms of myeloid leukemia, 3D animation with basic narration
View the animation to find out how the drug Gleevec™ inhibits the molecular cause of chronic myeloid leukemia.
Cold Spring Harbor Laboratory
CSHL HomeAbout CSHLResearchEducationPublic EventsNewsstandPartner With UsGiving